Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers

Journal of Clinical Pharmacology

Volumn 42, Issue 7, 2002, Pages 782-790

  Matsuno, Hiroyuki ^a   Uematsu, Toshihiko ^a   Niwa, Masayuki ^a   Kozawa, Osamu ^a   Nagashima, Satoru ^b   Kohno, Ken Ichi ^b   Kato, Hiroki ^c   Kawabata, Yoshihiro ^c   Yoshida, Yasuhisa ^c   Kanamaru, Mitsutaka ^b  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shitoro Clinic   (Japan)

^c ZERIA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; COLLAGEN; PLACEBO; SODIUM [2 (4 CHLOROPHENYLSULFONYLAMINOMETHYL)INDAN 5 YL]ACETATE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; Z 335; ANTITHROMBOCYTIC AGENT; INDAN DERIVATIVE; THROMBOXANE RECEPTOR;

ADULT; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; SIDE EFFECT; THROMBOCYTE AGGREGATION; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; ORAL DRUG ADMINISTRATION; TIME; URINE;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; INDANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; HUMANS;

EID: 0035998757     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401102722     Document Type: Article

References (15)

1. 2 and prostacyclin
2. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers
3. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers
4. 2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells
5. 2 modulates the fibrinolytic system in glomerular mesangial cells
6. Role of nitric oxide and thromboxane in the maintenance of cerebrovascular tone
7. 2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics
8. 2 receptor antagonist, on airway inflammation in subjects with asthma
9. Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist
10. A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time
11. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro
12. The pharmacokinetics and pharmacodynamic profiles of the thromboxane receptor blocker BM13.177
13. Single dose pharmacokinetics and effects on platelet function of the thromboxane receptor blocker BM13.177
14. Quantitation of drug levels and platelet receptor blockade caused by a thromboxane antagonist
15. Characteristics of 3H-GR32192 binding to the thromboxane (TP) receptor of human platelets